

Status: Currently Official on 14-Feb-2025
Official Date: Official as of 31-Mar-2022
Document Type: USP Monographs
DocId: GUID-A38E8EA1-AB90-4935-880A-0106A2DBC26E_3_en-US
DOI: https://doi.org/10.31003/USPNF_M5093_03_01
DOI Ref: eks70

© 2025 USPC
Do not distribute

Diclofenac Potassium for Oral Solution

DEFINITION

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click www.uspnf.com/rb-diclofenac-na-for-os-20220429.

Diclofenac Potassium for Oral Solution contains NLT 95.0% and NMT 105.0% of the labeled amount of diclofenac potassium ($C_{14}H_{10}Cl_2NKO_2$).

IDENTIFICATION

- A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: Dissolve 1.56 g of [monobasic sodium phosphate dihydrate](#) in 1000 mL of [water](#). Adjust with [phosphoric acid](#) to a pH of 2.5.

Solution B: Dissolve 6.8 g of [monobasic potassium phosphate](#) and 0.88 g of [sodium hydroxide](#) in 1000 mL of [water](#). Adjust with 1 N [sodium hydroxide](#) to a pH of 6.8.

Mobile phase: [Acetonitrile](#) and *Solution A* (40:60)

Diluent: [Methanol](#) and *Solution B* (10:90)

Standard solution: 0.2 mg/mL of [USP Diclofenac Potassium RS](#) in *Diluent*. Sonicate to dissolve, if needed.

Sample stock solution: Nominally 0.5 mg/mL of diclofenac potassium prepared as follows. Transfer a portion of finely powdered contents of NLT 5 packets of Diclofenac Potassium for Oral Solution, equivalent to 100 mg of diclofenac potassium, to a 200-mL volumetric flask. Add 140 mL of *Diluent*, and sonicate for about 10 min. Dilute with *Diluent* to volume. Centrifuge a portion of the solution.

[NOTE—A centrifuge speed of 3500 rpm for 10 min may be suitable.]

Sample solution: Nominally 0.2 mg/mL of diclofenac potassium in *Diluent* from the *Sample stock solution*. Pass through a suitable filter of 0.45-µm pore size.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 254 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 15-cm; 5-µm packing [L1](#)

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 20 µL

Run time: NLT 1.4 times the retention time of diclofenac

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of diclofenac potassium ($C_{14}H_{10}Cl_2NKO_2$) in the portion of Diclofenac Potassium for Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of diclofenac from the *Sample solution*

r_S = peak response of diclofenac from the *Standard solution*

C_S = concentration of [USP Diclofenac Potassium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of diclofenac potassium in the *Sample solution* (mg/mL)

PERFORMANCE TESTS

• [DISSOLUTION \(711\)](#)

Medium: pH 6.8 phosphate buffer (19 g/L of [trisodium phosphate dodecahydrate](#) in 0.1 N [hydrochloric acid](#), adjusted with 1 N [sodium hydroxide](#) to a pH of 6.8); 400 mL

Apparatus 2: 75 rpm

Time: 5 min

Solution A and Chromatographic system: Proceed as directed in the Assay.

Mobile phase: [Acetonitrile](#) and *Solution A* (50:50)

Standard solution: 0.125 mg/mL of [USP Diclofenac Potassium RS](#) prepared as follows. Transfer a quantity of [USP Diclofenac Potassium RS](#) to a suitable volumetric flask. Add [methanol](#) to 5% of the flask volume and sonicate to dissolve. Dilute with *Medium* to volume.

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45-µm pore size.

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of diclofenac potassium ($C_{14}H_{10}Cl_2NKO_2$) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

r_U = peak response of diclofenac from the *Sample solution*

r_S = peak response of diclofenac from the *Standard solution*

C_S = concentration of [USP Diclofenac Potassium RS](#) in the *Standard solution* (mg/mL)

V = volume of *Medium*, 400 mL

L = label claim of diclofenac potassium (mg/packet)

Tolerances: NLT 80% (Q) of the labeled amount of diclofenac potassium ($C_{14}H_{10}Cl_2NKO_2$) is dissolved.

• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

IMPURITIES

• ORGANIC IMPURITIES

Solution A: Prepare as directed in the Assay.

Solution B: Dissolve 6.8 g of [monobasic potassium phosphate](#) in 1000 mL of [water](#). Adjust with 1 N [sodium hydroxide](#) to a pH of 6.8.

Mobile phase: [Methanol](#) and *Solution A* (66:34)

Diluent: [Methanol](#) and *Solution B* (10:90)

Sensitivity solution: 0.5 µg/mL of [USP Diclofenac Potassium RS](#) in *Diluent*

Standard stock solution: 0.15 mg/mL of [USP Diclofenac Related Compound A RS](#) in [methanol](#)

Standard solution: 1 µg/mL of [USP Diclofenac Related Compound A RS](#) and 2.5 µg/mL of [USP Diclofenac Potassium RS](#), prepared as follows. Transfer a volume of *Standard stock solution* and a quantity of [USP Diclofenac Potassium RS](#) to a suitable volumetric flask, and add *Diluent* to dissolve. Sonicate if needed. Dilute with *Diluent* to volume.

Sample solution: Nominally 500 µg/mL of diclofenac potassium in *Diluent*, prepared as follows. Transfer a portion of finely powdered contents of NLT 5 packets of Diclofenac Potassium for Oral Solution, equivalent to 50 mg of diclofenac potassium, to a 100-mL volumetric flask. Add 70 mL of *Diluent*, and sonicate for 10 min. Dilute with *Diluent* to volume. Pass a portion of the solution through a suitable filter of 0.45-µm pore size, and discard the first 5 mL of the filtrate.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; 5-µm packing [L7](#)

Flow rate: 1 mL/min

Injection volume: 25 µL

Run time: NLT 2.2 times the retention time of diclofenac

System suitability

Samples: *Sensitivity solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times.]

Suitability requirements

Relative standard deviation: NMT 5.0% for diclofenac and diclofenac related compound A, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of diclofenac related compound A in the portion of Diclofenac Potassium for Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of diclofenac related compound A from the *Sample solution*

r_S = peak response of diclofenac related compound A from the *Standard solution*

C_S = concentration of [USP Diclofenac Related Compound A RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of diclofenac potassium in the *Sample solution* (µg/mL)

Calculate the percentage of any unspecified degradation product in the portion of Diclofenac Potassium for Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of any unspecified degradation product from the *Sample solution*

r_S = peak response of diclofenac from the *Standard solution*

C_S = concentration of [USP Diclofenac Potassium RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of diclofenac potassium in the *Sample solution* (µg/mL)

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Diclofenac related compound A	0.6	0.2
Diclofenac	1.0	—
Any unspecified degradation product	—	0.2
Total degradation products	—	1.0

SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): The total aerobic microbial count is NMT 10³ cfu/g. The total combined yeasts and molds count is NMT 10² cfu/g. It meets the requirements of the test for absence of *Escherichia coli*.

Change to read:

- [pH \(791\)](#).

Sample: Dissolve the contents of a unit dosage of Diclofenac Potassium for Oral Solution in 30 mL of [water](#).

Acceptance criteria: 7.0–▲11.5▲ (RB 31-Mar-2022)

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Store at controlled room temperature.
- [USP REFERENCE STANDARDS \(11\)](#).

[USP Diclofenac Potassium RS](#)

[USP Diclofenac Related Compound A RS](#)

1-(2,6-Dichlorophenyl)indolin-2-one.

C₁₄H₉Cl₂NO 278.13

Topic/Question	Contact	Expert Committee
DICLOFENAC POTASSIUM FOR ORAL SOLUTION	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(3)

Current DocID: GUID-A38E8EA1-AB90-4935-880A-0106A2DBC26E_3_en-US

DOI: https://doi.org/10.31003/USPNF_M5093_03_01

DOI ref: [eks70](#)

OFFICIAL